{"context":{"query":">>chembl_molecule>>clinical_trials","source_dataset":"chembl_molecule","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]CHEMBL2364655,22,CHEMBL2364655,141,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"CHEMBL2364655","source":"CHEMBL2364655|EVOLOCUMAB","targets":["NCT02948777|Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes|COMPLETED|PHASE4|INTERVENTIONAL","NCT03096288|Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity|COMPLETED|PHASE4|INTERVENTIONAL","NCT03258281|Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus|TERMINATED|PHASE4|INTERVENTIONAL","NCT03331666|Impact of LDL-cholesterol Lowering on Platelet Activation|TERMINATED|PHASE4|INTERVENTIONAL","NCT03403374|Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia|COMPLETED|PHASE4|INTERVENTIONAL","NCT03829046|The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT03851263|Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT03900026|Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery|COMPLETED|PHASE4|INTERVENTIONAL","NCT03932721|EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial|COMPLETED|PHASE4|INTERVENTIONAL","NCT04073134|The CHORAL Flow Study|TERMINATED|PHASE4|INTERVENTIONAL","NCT04100434|Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04397653|Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04510844|Evolocumab In Advanced Chronic Kidney Disease Trial|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT04539223|A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04573777|Reducing Intracranial atheroSclErosis With Repatha|TERMINATED|PHASE4|INTERVENTIONAL","NCT04608474|Lipid Management in Renal Transplant Recipients Using Evolocumab.|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04659525|Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04710368|Effect of Evolocumab on Coronary Plaque Characteristics|COMPLETED|PHASE4|INTERVENTIONAL","NCT04719221|Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04730973|CARotid plaqUe StabilizatiOn and Regression With Evolocumab.|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04951856|Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT05152888|The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk|RECRUITING|PHASE4|INTERVENTIONAL","NCT05284747|EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT05579418|The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05585151|High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05613426|Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI|RECRUITING|PHASE4|INTERVENTIONAL","NCT05641753|Cholesterol Lowering and Residual Risk in Diabetes, Type 1|RECRUITING|PHASE4|INTERVENTIONAL","NCT05661552|Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI|COMPLETED|PHASE4|INTERVENTIONAL","NCT05697185|Safety and Efficacy of Evolocumab in Ischemic Stroke|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05976893|Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06231459|Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia|COMPLETED|PHASE4|INTERVENTIONAL","NCT01516879|Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study|COMPLETED|PHASE3|INTERVENTIONAL","NCT01588496|Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01624142|Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01763827|Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2|COMPLETED|PHASE3|INTERVENTIONAL","NCT01763866|LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2|COMPLETED|PHASE3|INTERVENTIONAL","NCT01763905|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2|COMPLETED|PHASE3|INTERVENTIONAL","NCT01763918|Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2|COMPLETED|PHASE3|INTERVENTIONAL","NCT01764633|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk|COMPLETED|PHASE3|INTERVENTIONAL","NCT01813422|GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound|COMPLETED|PHASE3|INTERVENTIONAL","NCT01854918|Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia|COMPLETED|PHASE3|INTERVENTIONAL","NCT01953328|Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk|COMPLETED|PHASE3|INTERVENTIONAL","NCT01984424|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3|COMPLETED|PHASE3|INTERVENTIONAL","NCT02189837|Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody|COMPLETED|PHASE3|INTERVENTIONAL","NCT02207634|Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects|COMPLETED|PHASE3|INTERVENTIONAL","NCT02304484|Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab|COMPLETED|PHASE3|INTERVENTIONAL","NCT02392559|Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders|COMPLETED|PHASE3|INTERVENTIONAL","NCT02585895|Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment|COMPLETED|PHASE3|INTERVENTIONAL","NCT02624869|Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02634580|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4|COMPLETED|PHASE3|INTERVENTIONAL","NCT02662569|Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia|COMPLETED|PHASE3|INTERVENTIONAL","NCT02729025|Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))|COMPLETED|PHASE3|INTERVENTIONAL","NCT02739984|Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia|COMPLETED|PHASE3|INTERVENTIONAL","NCT02833844|Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia|COMPLETED|PHASE3|INTERVENTIONAL","NCT02867813|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension|COMPLETED|PHASE3|INTERVENTIONAL","NCT03080935|Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries|TERMINATED|PHASE3|INTERVENTIONAL","NCT03287609|EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03429998|Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia|COMPLETED|PHASE3|INTERVENTIONAL","NCT03433755|Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia|TERMINATED|PHASE3|INTERVENTIONAL","NCT03570697|Imaging of Coronary Plaques in Participants Treated With Evolocumab|COMPLETED|PHASE3|INTERVENTIONAL","NCT03689946|Effect of Evolocumab on Coronary Atherosclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT03734211|Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients|COMPLETED|PHASE3|INTERVENTIONAL","NCT03872401|Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke|COMPLETED|PHASE3|INTERVENTIONAL","NCT04034485|Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH|COMPLETED|PHASE3|INTERVENTIONAL","NCT04665830|PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT04790513|Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT04941105|Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19|COMPLETED|PHASE3|INTERVENTIONAL","NCT05741086|Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01375751|Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT01375764|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects|COMPLETED|PHASE2|INTERVENTIONAL","NCT01375777|Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels|COMPLETED|PHASE2|INTERVENTIONAL","NCT01380730|LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy|COMPLETED|PHASE2|INTERVENTIONAL","NCT01439880|Open Label Study of Long Term Evaluation Against LDL-C Trial|COMPLETED|PHASE2|INTERVENTIONAL","NCT01652703|A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects|COMPLETED|PHASE2|INTERVENTIONAL","NCT03060577|An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol|COMPLETED|PHASE2|INTERVENTIONAL","NCT03193047|Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy|COMPLETED|PHASE2|INTERVENTIONAL","NCT03337698|A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT03500302|Effect of Evolocumab on Coronary Endothelial Function|COMPLETED|PHASE2|INTERVENTIONAL","NCT03515304|Evolocumab in Acute Coronary Syndrome|COMPLETED|PHASE2|INTERVENTIONAL","NCT03791593|EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot|COMPLETED|PHASE2|INTERVENTIONAL","NCT03869073|Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)|UNKNOWN|PHASE2|INTERVENTIONAL","NCT03944577|Impact of Evolocumab in Cardiac Transplant Patients With CAV|COMPLETED|PHASE2|INTERVENTIONAL","NCT04082442|Evolocumab in Patients With Acute MI|COMPLETED|PHASE2|INTERVENTIONAL","NCT04101643|PCSK9 Inhibitor Treatment for Patients With SPG5|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT04303377|Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT04338165|Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography|UNKNOWN|PHASE2|INTERVENTIONAL","NCT04992065|A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease|COMPLETED|PHASE2|INTERVENTIONAL","NCT05144529|A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT06284564|A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT06496243|Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels|RECRUITING|PHASE2|INTERVENTIONAL","NCT06700720|YN001-004 in Patients With Coronary Atherosclerosis in Australia|RECRUITING|PHASE2|INTERVENTIONAL","NCT01133522|Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin|COMPLETED|PHASE1|INTERVENTIONAL","NCT02275156|Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab|COMPLETED|PHASE1|INTERVENTIONAL","NCT04189484|Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors|COMPLETED|PHASE1|INTERVENTIONAL","NCT04937413|The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation|COMPLETED|EARLY_PHASE1|INTERVENTIONAL","NCT06081153|Mechanistic Clinical Trial of PCSK9 Inhibition for AAA|NOT_YET_RECRUITING|EARLY_PHASE1|INTERVENTIONAL","NCT06140095|Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism|UNKNOWN|EARLY_PHASE1|INTERVENTIONAL","NCT02957604|Evolocumab Pregnancy Exposure Registry|TERMINATED|nan|OBSERVATIONAL","NCT03247972|Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease|TERMINATED|nan|OBSERVATIONAL","NCT04087915|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)|UNKNOWN|nan|OBSERVATIONAL"]}]}